GSK plc × 23andMe Holding Co.
GSK exercised its option to extend its exclusive drug discovery collaboration with 23andMe for an additional year, from July 2022 to July 2023. [6, 8] For this extension, 23andMe received a one-time payment of $50 million. [6, 8] The collaboration, originally started in 2018, leverages 23andMe's vast database of genetic and health information from consenting customers to identify and validate new drug targets. [8, 10]
The asset
Exclusive access to 23andMe's de-identified genetic and health data for the purpose of drug target discovery.
- 40 drug discovery programs initiated under collaboration
The record
- Seller status
- Going concern
- Sector
- Consumer genetics and therapeutics
- Modalities
- genomic_data, phenotypic_data
- Jurisdiction
- US
- Personal data
- Data is de-identified. 23andMe performs statistical analysis in-house and shares summary results with GSK. [8]
What it means if you hold data
This deal highlights the continued high value placed on large-scale human genetic databases by major pharmaceutical companies for R&D. The recurring revenue demonstrates a mature, ongoing data licensing relationship built around a unique, proprietary dataset.